Last $29.38 USD
Change Today -0.265 / -0.89%
Volume 326.2K
MDCO On Other Exchanges
Symbol
Exchange
Munich
NASDAQ GS
As of 12:30 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

medicines company (MDCO) Snapshot

Open
$29.51
Previous Close
$29.64
Day High
$29.63
Day Low
$29.17
52 Week High
03/13/14 - $30.80
52 Week Low
10/14/14 - $19.92
Market Cap
1.9B
Average Volume 10 Days
969.1K
EPS TTM
$-0.07
Shares Outstanding
65.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDICINES COMPANY (MDCO)

medicines company (MDCO) Related Businessweek News

No Related Businessweek News Found

medicines company (MDCO) Details

The Medicines Company provides medicines for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria; Orbactiv for the treatment of acute bacterial skin and skin structure infections; PreveLeak, a mechanical vascular and surgical sealant; ready-to-use formulation of Argatroban for the treatment of thrombosis; and Recothrom, a human recombinant thrombin used as an aid to hemostasis, as well as acute care generic products for acute cardiovascular, surgery and perioperative care, and serious infectious diseases. Its development stage products include Cangrelor for the prevention of platelet activation and aggregation; IONSYS for the short-term management of acute postoperative pain; Raplixa, a dry powder topical formulation of fibrogen and thrombin; and RPX-602 for the treatment of bacterial infections. The company’s products under development also comprise ABP-700, an intravenous anesthetic agent for moderate or deep sedation and general anesthesia in patients undergoing diagnostic or therapeutic procedures; LN-PCSsc for the treatment of hypercholesterolemia; Carbavance, an antibiotic agent for the treatment of hospitalized patients with bacterial infections; and MDCO-216, a novel biologic product to reverse atherosclerotic plaque development and reduce the risk of ischemic events in patients with ACS. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize ALN-PCSsc. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

medicines company (MDCO) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $793.3K
President, Chief Financial Officer, Treasurer...
Total Annual Compensation: $569.3K
Chief Accounting Officer and Senior Vice Pres...
Total Annual Compensation: $398.2K
Compensation as of Fiscal Year 2013.

medicines company (MDCO) Key Developments

Medicines Company Seeks Financing

The Medicines Company (NasdaqGS:MDCO) is looking for financing for acquisitions. The Medicines Company stated, "We may seek additional financing to fund our acquisitions of development stage compounds, clinical stage product candidates and approved products and/or the companies that have such products."

The Medicines Company Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015

The Medicines Company Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015 . Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States.

The Medicines Company Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 08:30 AM

The Medicines Company Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 08:30 AM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Clive A. Meanwell, Chairman and Chief Executive Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDCO:US $29.38 USD -0.265

MDCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $68.16 USD -1.05
CR Bard Inc $167.29 USD -2.99
CryoLife Inc $10.72 USD -0.09
Integra LifeSciences Holdings Corp $59.10 USD -1.01
Medicure Inc C$1.88 CAD -0.06
View Industry Companies
 

Industry Analysis

MDCO

Industry Average

Valuation MDCO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.7x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDICINES COMPANY, please visit www.themedicinescompany.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.